Research Article

Interaction of Anticancer Drugs with Human Organic Anion Transporter hOAT4

Chenchang Liu, Jinghui Zhang, and Guofeng You

Departments of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, NJ, USA

Correspondence should be addressed to Guofeng You; gyou@pharmacy.rutgers.edu

Received 13 April 2018; Revised 13 June 2018; Accepted 13 February 2019; Published 28 February 2019

1. Introduction

Human organic anion transporter 4 (hOAT4) belongs to a family of multispecific organic anion transporters that play critical roles in the disposition of numerous drugs and therefore are the major sites for drug-drug interaction. Drug-drug interactions contribute significantly to the individual variation in drug response. hOAT4 is expressed in the kidney and placenta. In the current study, we examined the interaction of 36 anticancer drugs with hOAT4 in kidney COS-7 cells and placenta BeWo cells. Among the drugs tested, only epirubicin hydrochloride and dabrafenib mesylate exhibited > 50% cis-inhibitory effect, in COS-7 cells, on hOAT4-mediated uptake of estrone sulfate, a prototypical substrate for the transporter. The IC_{50} values for epirubicin hydrochloride and dabrafenib mesylate were 5.24 ± 0.95 μM and 8.30 ± 3.30 μM, respectively. Dixon plot analysis revealed that inhibition by epirubicin hydrochloride was noncompetitive with a K_{i} = 3 μM whereas inhibition by dabrafenib mesylate was competitive with a K_{i} = 4.26 μM. Our results established that epirubicin hydrochloride and dabrafenib mesylate are inhibitors of hOAT4. Furthermore, by comparing our data with clinically relevant exposures of these drugs, we conclude that although the tendency for dabrafenib mesylate to cause drug-drug interaction through hOAT4 is insignificant in the kidney, the propensity for epirubicin hydrochloride to cause drug-drug interaction is high.
hOAT4 with additional 36 FDA-approved anticancer drugs in the same library which were updated after our previous publication.

2. Materials and Methods

2.1. Reagents. The National Institute of Health/National Cancer Institute (NIH/NCI) oncology drug set IV plate, plate key: 4762074 (AOD4-AOD8), was acquired from NCI Chemotherapeutic Agents Repository, Fisher Biocentrics. AOD 4 (drug set IV plate) contains 101 drugs which were previously examined by our lab [14]. AOD 4 (drug set IV plate) was updated to AOD 8 (drug set IV plate) after our previous publication by adding 36 new drugs into the library. The updated 36 drugs in AOD 8 were examined in the current studies. [3H]-estrone sulfate (ES) was obtained from PerkinElmer Life and Analytical Sciences (Waltham, MA). COS-7 cells were purchased from American Type Culture Collection (Manassas, VA). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless stated otherwise.

2.2. Cell Culture. Parental COS-7 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) (1% CO2 atmosphere at 37°C). COS-7 cells and BeWo cells stably expressing hOAT4 were previously established in our lab and the culture conditions for these cells were previously described by our lab [7, 15].

2.3. Transport Measurements. Cells were plated at a density of 120,000 cells/well in 48-well plate. Uptake solution was consisted of phosphate-buffered saline (PBS) (1 mM CaCl2, 1 mM MgCl2, pH7.4) and 300 nM [3H]-ES. The uptake experiments were conducted for 4 minutes at room temperature with indicated concentrations of test compounds in the figure legends. Uptake was terminated with rapid washing of the cells with 500 μL ice-cold PBS solution twice. Cells were lysed in 0.2 N NaOH, neutralized in 0.2 N HCl, and placed in individual scintillation vials. Radioactivity was measured using Beckman LC6500 scintillation counter.

2.4. Concentration-Dependent Inhibition Studies. Inhibition studies were performed at varying concentrations of epirubicin hydrochloride or dabrafenib mesylate. hOAT4-specific uptake was obtained by subtracting [3H]-ES uptake into parental cells from the uptake into hOAT4-expressing cells. The IC50 (concentration of the drugs required to inhibit 50% of ES uptake) was determined by nonlinear regression using GraphPad Prism.

2.5. Dixon Plot. The mechanism of inhibition was determined by linear regression analysis of reciprocal saturable uptake (1/i) for different substrate concentrations (1.2 μM or 2.4 μM ES) as a function of inhibitor concentration. hOAT4 uptake was determined at 4 minutes in both the absence and presence of varying concentrations of epirubicin hydrochloride or dabrafenib mesylate. The specific uptake was obtained by subtracting [3H]-ES uptake into parental cells from the uptake into hOAT4-expressing cells. The data were analyzed by linear regression with GraphPad Prism. Kᵢ values were calculated from the intersection of lines representing [ES] =1.2 μM and [ES] = 2.4 μM.

2.6. Trans Effect Study. For trans effect study, cells expressing hOAT4 were preloaded with dabrafenib mesylate (100 mM) or ES (100 mM), respectively, for 1 hour at 37°C to allow the chemical substances to diffuse into the cells, followed by rapid washing and subsequent exposure to uptake solution consisted of phosphate-buffered saline (PBS) (1 mM CaCl2, 1 mM MgCl2, pH7.4) and 300 nM [3H]-ES. Uptake experiment was preceded as described above.

2.7. Statistical Analysis. Each experiment was repeated three times. Statistical analysis was performed using GraphPad Prism software (GraphPad Software Inc., San Diego, CA), one-way ANOVA, multiple comparisons Tukey’s test. A p value of <0.05 was considered significant.

3. Results

3.1. Cis Effects of Anticancer Drugs on hOAT4-Mediated Uptake of Estrone Sulfate (ES) in Monkey Kidney COS-7 Cells. To investigate the effect of 36 FDA-approved anticancer drugs on hOAT4-mediated uptake of ES, cis-inhibition studies were performed in hOAT4-expressing COS-7 cells. “cis” indicates that both ES and drugs are present on the same side of the cell membrane. Although many of the drugs tested demonstrated some level of inhibition or stimulation, only epirubicin hydrochloride and dabrafenib mesylate demonstrated greater than 50% suppression of hOAT4-mediated [3H]-ES uptake at the indicated concentration (Figure 1). Drugs short of significant effects (either inhibitory or stimulatory) suggest a lack of hOAT4 interaction. Thus, their probabilities to cause drug interactions via hOAT4 inhibition can be excluded. Probenecid, a known inhibitor for OAT family members [16], was used as an inhibitor control for this study. We therefore, focus on epirubicin hydrochloride and dabrafenib mesylate in the following studies.

3.2. Cis Effects of Epirubicin Hydrochloride and Dabrafenib Mesylate on hOAT4-Mediated ES Uptake in Human Placental BeWo Cells. hOAT4 is expressed in both the kidney and placenta. The inhibition effects of epirubicin hydrochloride and dabrafenib mesylate were next characterized in human placental BeWo cells stably expressing hOAT4. At the concentration of 100 μM, both epirubicin hydrochloride and dabrafenib mesylate resulted in significant inhibition of hOAT4-mediated ES uptake in these cells (Figure 2).

3.3. Dose-Dependent Effects of Epirubicin Hydrochloride and Dabrafenib Mesylate on hOAT4-Mediated ES Uptake. We next constructed dose response curves to evaluate the effectiveness of epirubicin hydrochloride and dabrafenib mesylate as inhibitors of hOAT4-mediated transport in COS-7 cells. Epirubicin hydrochloride (Figure 3(a)) and dabrafenib mesylate (Figure 3(b)) significantly inhibited hOAT4-mediated ES uptake in a concentration-dependent manner with IC50 values of 5.24±0.95 μM and 8.30±3.30 μM, respectively.
Journal of Oncology

Probenecid
Afatinib
Olaparib
Palbociclib
Cabozantinib
Panobinostat
Erismodegib
Ibrutinib
Regorafenib
Alectinib
Dabrafenib mesylate
Bosutinib
Venetoclax
Cobimetinib
Pomalidomide
Ceritinib
Ribociclib
Osimertinib
Niraparib hydrochloride
Idarubicin hydrochloride
Epirubicin hydrochloride
Temsirolimus
Enzalutamide
Lenvatinib
Nelarabine
Bortezomib
Trametinib
Omacetaxine mepesuccinate
Ixazomib citrate
Ponatinib
Belinostat
Idelalisib
Uridine triacetate
Plerixafort
Pemetrexed, Disodium salt, Heptahydrate
Rucaparib phosphate

Figure 1: Interaction of hOAT4 with 36 anticancer drugs. hOAT4-mediated \(^{3}H\)-ES uptake was measured in COS-7 cells stably expressing hOAT4. The 4-min uptake of 300 nM \(^{3}H\)-ES in the absence (control) or presence of test compounds (10 \(\mu M\)) was measured. Each data point represents only carrier-mediated transport after subtraction of values from parental cells. Uptake activity was expressed as percentage of uptake measured in control cells. Results shown are means ± SE (n=3).

3.4. Dixon Plot Analysis. To further dissect the mechanism of inhibition and to determine the \(K_I\) values (inhibition constants), uptake in the absence and presence of epirubicin hydrochloride or dabrafenib mesylate was analyzed via Dixon plot (Figure 4). Epirubicin hydrochloride demonstrated a noncompetitive mechanism of inhibition of ES uptake by hOAT4 (as the lines for substrate concentrations converge at the x axis) with a \(K_I\) value of 3 \(\mu M\) (Figure 4(a)), whereas dabrafenib mesylate demonstrated a competitive mechanism of inhibition of ES uptake by hOAT4 (as the lines for substrate concentrations converge above the x axis) with a \(K_I\) value of 4.26 \(\mu M\) (Figure 4(b)) [17].

3.5. Trans Effect of Dabrafenib Mesylate on hOAT4-Mediated Transport. Trans effect studies are not needed for epirubicin hydrochloride since it was demonstrated to be a noncompetitive hOAT4 inhibitor in previous experiments. For dabrafenib mesylate, it was shown to be a competitive inhibitor, but it is uncertain whether dabrafenib mesylate could be a substrate and transported by hOAT4. Therefore, trans effect on hOAT4-mediated transport by dabrafenib mesylate was investigated (Figure 5). If the presence of dabrafenib mesylate increases the flux of labeled substrates in the opposite side of the membrane, it would be expected as a substrate of hOAT4; If dabrafenib mesylate tends to bind to the carrier and prevents it from being available for other substrates, instead of transported by hOAT4, then tran-sinhibition would take place. Dabrafenib mesylate showed the trans-inhibition of uptake of radio-labeled OAT substrates rather than tran-stimulation shown by positive control. Therefore, dabrafenib mesylate is not a substrate for hOAT4.

4. Discussion
The drug disposition by hOAT4 plays an important role in determining drug efficacy and toxicity. The interaction of hOAT4 with various compounds was reported by other labs including Chinese herbal medicine, angiotensin II receptor antagonists, leukotriene receptor antagonists, nonsteroidal anti-inflammatory drugs and diuretics [5, 10, 18]. Previously we examined the interactions of 101 anticancer drugs
We next characterized the interaction of hOAT4 with epirubicin hydrochloride and dabrafenib mesylate in human placenta BeWo cells, and we observed some differences between placenta BeWo cells and kidney COS-7 cells. In COS-7 cells at 10 μM, both epirubicin hydrochloride and dabrafenib mesylate inhibited uptake of estrone sulfate by more than 50%, with epirubicin hydrochloride being more potent than dabrafenib mesylate. However, in BeWo cells at 100 μM only dabrafenib mesylate inhibited by more than 50% and epirubicin hydrochloride inhibition was only about 30%. Such observation is interesting. Our lab previously demonstrated that the regulation of hOAT4 transport activity is different between kidney cells and BeWo cells due to different sets of regulatory proteins that interact with hOAT4 [21]. Therefore, our current observation that epirubicin hydrochloride and dabrafenib mesylate showed different inhibition potency on hOAT4 transport activity once again confirmed that the functional characteristics of hOAT4 are different between kidney cells and placenta cells.

In our current study, The IC\textsubscript{50} values of epirubicin hydrochloride and dabrafenib mesylate for hOAT4 are determined as 5.24±0.95 μM and 8.30±3.30 μM, respectively (Figures 3(a) and 3(b)). The peak plasma epirubicin hydrochloride concentration (C\textsubscript{max}) suggested by FDA drug product label is 17.2 μM [22]. Corrected by unbound fraction value of 0.23, the unbound maximum plasma concentration (C\textsubscript{u,max}) of epirubicin hydrochloride is around 4 μM. As for dabrafenib mesylate, the maximum plasma concentration (C\textsubscript{max}) is 1.31 μM [23]. Corrected by unbound fraction value of 0.003, according to datasheet provided by FDA [24], the unbound maximum plasma concentration (C\textsubscript{u,max}) of dabrafenib mesylate is around 0.0039 μM. A C\textsubscript{u,max}/IC\textsubscript{50} value greater than 0.1 suggests a potential for drug-drug interaction [25]. Since C\textsubscript{u,max}/IC\textsubscript{50} value of epirubicin hydrochloride for hOAT4 is greater than 0.1, while C\textsubscript{u,max}/IC\textsubscript{50} value of dabrafenib mesylate for hOAT4 is much lower than 0.1, this result suggested that the potential for epirubicin hydrochloride to cause drug-drug interaction through inhibition of hOAT4 is high whereas the potential for dabrafenib mesylate to cause drug-drug interaction through inhibition of hOAT4 is less significant.

The inhibition mechanisms for both drugs were also demonstrated by Dixon plot in our study, which revealed that the modes of action of epirubicin hydrochloride and dabrafenib mesylate are distinct. Epirubicin hydrochloride revealed a noncompetitive mechanism of inhibition of ES uptake through hOAT4 (Figure 4(a)), where the activity of the transporter is decreased by the inhibitor by binding to an area other than the substrate binding site. The transporter activity could be reduced through the structure change/steric effect [26]. In contrast, dabrafenib mesylate revealed a competitive mechanism of inhibition of ES uptake through hOAT4 (Figure 4(b)), where the inhibitor binds to the active site on the transporter to prevent the binding between transporter and its substrate. To explore why epirubicin hydrochloride and dabrafenib mesylate showed different inhibitory mechanisms of ES uptake by hOAT4, we compared chemical structures (Figure 6) and physicochemical features of epirubicin hydrochloride, dabrafenib mesylate and estrone sulfate.
Figure 3: Dose-dependent inhibition of hOAT4-mediated uptake by epirubicin hydrochloride and dabrafenib mesylate. Stable hOAT4-expressing COS-7 cells were incubated for 4 mins with PBS containing 300 nM [3H]-ES in the presence or absence of various concentrations of epirubicin hydrochloride (a) or dabrafenib mesylate (b). Each data point represents only carrier-mediated transport after subtraction of values from parental cells. Uptake activity was expressed as percentage of uptake measured in control cells. Results shown are means ± SE (n=3). Data were analyzed statistically with ANOVA, followed by Tukey’s post hoc test. ∗p < 0.05. The line represents a best fit of data using nonlinear regression analysis.

Figure 4: Dixon plot analysis of the inhibitory effects of epirubicin hydrochloride and dabrafenib mesylate on hOAT4-mediated transport in COS-7 cells. 1.2 μM and 2.4 μM [3H]-ES uptake was determined at 4 mins in the absence or presence of varying concentrations of epirubicin hydrochloride (a) or dabrafenib mesylate (b). Each data point represents only carrier-mediated transport after subtraction of values from parental cells. Results shown are means ± SE (n=3). The data was fitted by linear regression and Kᵢ was calculated. For epirubicin hydrochloride, Kᵢ = 3 μM and intersection is (-3, 0); for dabrafenib mesylate, Kᵢ = 4.26 μM and intersection is (-4.26, 0.03).
Figure 5: Trans effect of dabrafenib mesylate on hOAT4-mediated transport in COS-7 cells. Cells expressing hOAT4 were preloaded (PL) with dabrafenib mesylate (Dab, 100 mM) or unlabeled hOAT4 substrate estrone sulfate (100 mM) for 1 h, followed by washing with PBS and a subsequent exposure (EXP) to PBS containing $^3$H-labeled estrone sulfate (300 nM). 4 min later, the uptake was stopped by rapidly washing the cells with ice-cold PBS. Intracellular accumulation of $^3$H-labeled estrone sulfate was then counted. Each data point represents only carrier-mediated transport after subtraction of values from parental cells and was expressed as a percentage of the uptake measured in cells without preloading with dabrafenib mesylate or positive control. The results shown are means ± SE (n = 3). *p < 0.05.

Figure 6: Chemical structures of estrone sulfate, epirubicin hydrochloride, and dabrafenib mesylate.

(values are calculated by Chemicalized Platform, ChemAxon, USA) (Table 1). By analysis, dabrafenib mesylate is more similar to estrone sulfate than epirubicin hydrochloride in terms of octanol-water partition coefficient Log P, the number of rings, polar surface area, hydrogen-bond donor count, and hydrogen-bond acceptor count, suggesting that structurally dabrafenib mesylate is more similar to estrone sulfate as compared to epirubicin hydrochloride. Other properties in the table do not show any differences among the three compounds. The structural similarity between dabrafenib mesylate and estrone sulfate explains the competitive inhibition effect of dabrafenib mesylate on ES uptake by hOAT4.

5. Conclusion

Our results demonstrated that both epirubicin hydrochloride and dabrafenib mesylate are inhibitors for hOAT4. However, only epirubicin hydrochloride might cause significant drug-drug interaction in kidney cells, whereas the propensity of dabrafenib mesylate to cause drug-drug interaction is very low. Therefore, drug-drug interactions between epirubicin hydrochloride and drugs which are OAT4 substrates should be carefully considered while taken together.

Indeed, OAT4 plays a key role in vivo. For example, lesinurad, Benzbromarone, and Probenecid inhibit kidney OAT4 to block the uric acid reabsorption [27]. Cigarette smoke condensate has also been reported to have inhibitory effect on OAT4 [28]. Understanding hOAT4-mediated drug-drug interaction and the regulation of hOAT4 is of clinical and pharmacological significance.

Data Availability
The data used to support the findings of this study are included within the article.
Table 1: Physicochemical characteristics of estrone sulfate, epirubicin hydrochloride, and dabrafenib mesylate.

<table>
<thead>
<tr>
<th></th>
<th>Estrone Sulfate</th>
<th>Epirubicin Hydrochloride</th>
<th>Dabrafenib Mesylate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Weight</td>
<td>350.43</td>
<td>379.99</td>
<td>615.65</td>
</tr>
<tr>
<td>Log P</td>
<td>3.83</td>
<td>0.9</td>
<td>5.46</td>
</tr>
<tr>
<td>Physiological Charge</td>
<td>-1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Hydrogen Acceptor Count</td>
<td>4</td>
<td>12</td>
<td>6</td>
</tr>
<tr>
<td>Hydrogen Donor Count</td>
<td>1</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>Polar Surface Area</td>
<td>80.67</td>
<td>206.07</td>
<td>110.86</td>
</tr>
<tr>
<td>Rotatable Bond Count</td>
<td>2</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Polarizability</td>
<td>36.64</td>
<td>53.88</td>
<td>49.71</td>
</tr>
<tr>
<td>Number of Rings</td>
<td>4</td>
<td>5</td>
<td>4</td>
</tr>
</tbody>
</table>

Values are calculated by Chemicalized Platform, ChemAxon, USA.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Chenchang Liu and Jinghui Zhang contributed equally and shared first authorship.

Acknowledgments

This work was supported by the National Institutes of Health to Dr. Guofeng You: National Institute of General Medical Sciences (R01-GM079123 and R01-GM097000).

References


